论文部分内容阅读
目的观察黄芪多糖协同I125治疗中晚期肺癌的临床疗效。方法将35例中晚期肺癌患者随机分为I125单纯治疗组(A组)17例和黄芪多糖+I125协同治疗组(B组),比较治疗前后两组患者瘤体大小、免疫功能指标、肿瘤标志物水平。结果 A、B两组近期有效率分别为70.6%和77.8%,B组有提高有效率的趋势,但无统计学意义(P>0.05)。B组治疗后T细胞亚群CD3+、CD4+、NK明显升高,CD8+明显下降,治疗后CD4+/CD8+与A组比较,差异有显著性意义(P<0.05)。A、B两组肿瘤标志物CEA、CYFRA-21治疗前后比较差异明显(P<0.05),治疗后B组患者的CEA、CYFRA-21水平与A组比较,差异明显。结论黄芪多糖协同碘125治疗中晚期肺癌疗效肯定,具有减毒增效作用。
Objective To observe the clinical efficacy of Astragalus Polysaccharides in combination with I125 in the treatment of advanced lung cancer. Methods 35 patients with advanced lung cancer were randomly divided into I125 treatment group (A group) 17 cases and Astragalus polysaccharide + I125 treatment group (B group), before and after treatment in both groups tumor size, immune function, tumor markers Material level. Results The effective rates of A and B in two groups were 70.6% and 77.8%, respectively. There was a trend of increasing efficiency in group B, but there was no statistical significance (P> 0.05). After treatment, the levels of CD3 +, CD4 + and NK in T lymphocyte subsets in group B were significantly increased, while the levels of CD8 + in group B were significantly decreased. There was significant difference between CD4 + / CD8 + and group A after treatment (P <0.05). The difference of CEA and CYFRA-21 between group A and B before and after treatment was significant (P <0.05). The level of CEA and CYFRA-21 in group B was significantly different from that in group A after treatment. Conclusion Astragalus Polysaccharides synergistic with iodine 125 treatment of advanced lung cancer with a positive effect, with attenuated synergistic effect.